Importantly, our findings revealed that these effects were mediated in part through suppression of TGF-β1/Smad signaling pathway, suggesting that ginsenoside Rg1 could be a therapeutic target for airway remodeling in COPD. The gene discussed is TGFB1; the disease is chronic obstructive pulmonary disease.